WO2025167900 - AURISTATIN ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/167900
Publication Date
14.08.2025
International Application No.
PCT/CN2025/075767
International Filing Date
05.02.2025
Title **
[English]
AURISTATIN ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF
[French]
CONJUGUÉ ANTICORPS-MÉDICAMENT À BASE D'AURISTATINE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
[Chinese]
澳瑞他汀类抗体药物偶联物及其制备方法和应用
Applicants **
SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD.
Inventors
WEI, Wei
WANG, Wei
BAI, Yuanchao
WANG, Xiang
YANG, Hui
YANG, Yang
TAO, Weikang
Priority Data
202410171620.5
06.02.2024
CN
202410629033.6
20.05.2024
CN
202411305282.6
18.09.2024
CN
202411875514.1
18.12.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2154 | |
| EPO | Filing, Examination, Granting | 13730 | |
| Japan | Filing, Examination, Granting | 2313 | |
| South Korea | Filing, Examination, Granting | 2505 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
25,442
Contact Us
Abstract[English]
The present invention belongs to the technical field of medicinal chemistry, and particularly relates to an auristatin antibody-drug conjugate, a preparation method therefor, and use thereof. The antibody-drug conjugate has excellent DAR4 uniformity and drug activity, dynamic characteristics, and safety, and thus is suitable for preparing a drug for treating tumor-related diseases.[French]
La présente invention relève du domaine technique de la chimie médicale, et concerne en particulier un conjugué anticorps-médicament à base d'auristatine, son procédé de préparation et son utilisation. Le conjugué anticorps-médicament présente une excellente homogénéité du DAR4 et une excellente activité médicamenteuse, des caractéristiques dynamiques et une sécurité excellentes, et est ainsi approprié pour préparer un médicament pour le traitement de maladies liées à une tumeur.[Chinese]
属于药物化学技术领域，具体涉及澳瑞他汀类抗体药物偶联物及其制备方法和用途。该类抗体药物偶联物具有优良的DAR4均一度和药物活性、动力学特性和安全性，适合制备用于治疗肿瘤相关疾病的药物。